Predicting outcome in patients with sepsis: New biomarkers for old expectations

Critical Care

Volumn 18, Issue 1, 2014, Pages

  Charles, Pierre Emmanuel ^a   Gibot, Sébastien ^b  

^a HÔPITAL DU BOCAGE   (France)

^b UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; CD14 ANTIGEN; PEPTIDE FRAGMENT; PROTEIN PRECURSOR; SERUM ALBUMIN;

BLOOD; FEMALE; HUMAN; MALE; METABOLISM; SEPSIS;

ANTIGENS, CD14; CALCITONIN; FEMALE; HUMANS; MALE; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS; SEPSIS; SERUM ALBUMIN;

EID: 84893793382     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc13723     Document Type: Note

References (9)

1. Masson S, Caironi P, Spanuth E, Thomae R, Panigada M, Sangiorgi G, Fumagalli R, Mauri T, Isgro S, Fanizza C, Romero M, Tognoni G, Latini R, Gattinoni L. Presepsin (soluble CD14 subtype, sCD14-ST) and procalcitonin for early mortality prediction in severe sepsis and septic shock. A retrospective case-control study from the Albumin Italian Outcome Sepsis (ALBIOS) trial. Crit Care 2014, 18:R6. 10.1186/cc13183, 24393424.
2. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb S, Beale RJ, Vincent JL, Moreno R, Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013, 39:165-228. 10.1007/s00134-012-2769-8, 23361625, Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup.
3. Munford RS, Pugin J. Normal responses to injury prevent systemic inflammation and can be immunosuppressive. Am J Respir Crit Care Med 2001, 163:316-321. 10.1164/ajrccm.163.2.2007102, 11179099.
4. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Kumar A, Cheang M. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006, 34:1589-1596. 10.1097/01.CCM.0000217961.75225.E9, 16625125.
5. Charles PE, Tinel C, Barbar S, Aho S, Prin S, Doise JM, Olsson NO, Blettery B, Quenot JP. Procalcitonin kinetics within the first days of sepsis: relationship with the appropriateness of antibiotic therapy and the outcome. Crit Care 2009, 13:R38. 10.1186/cc7751, 2689475, 19291325.
6. Gibot S, Béné MC, Noel R, Massin F, Guy J, Cravoisy A, Barraud D, De Carvalho Bittencourt M, Quenot JP, Bollaert PE, Faure G, Charles PE. Combination biomarkers to diagnose sepsis in the critically ill patient. Am J Respir Crit Care Med 2012, 186:65-71. 10.1164/rccm.201201-0037OC, 22538802.
7. Ulla M, Pizzolato E, Lucchiari M, Loiacono M, Soardo F, Forno D, Morello F, Lupia E, Moiraghi C, Mengozzi G, Battista S. Diagnostic and prognostic value of presepsin in the management of sepsis in the emergency department: a multicenter prospective study. Crit Care 2013, 17:R168. 10.1186/cc12847, 23899120.
8. Bouadma L, Luyt CE, Tubach F, Cracco C, Alvarez A, Schwebel C, Schortgen F, Lasocki S, Veber B, Dehoux M, Bernard M, Pasquet B, Régnier B, Brun-Buisson C, Chastre J, Wolff M, PRORATA trial group Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010, 375:463-474. 10.1016/S0140-6736(09)61879-1, 20097417, PRORATA trial group.
9. Jensen JU, Hein L, Lundgren B, Bestle MH, Mohr TT, Andersen MH, Thornberg KJ, Løken J, Steensen M, Fox Z, Tousi H, Søe-Jensen P, Lauritsen A, Strange D, Petersen PL, Reiter N, Hestad S, Thormar K, Fjeldborg P, Larsen KM, Drenck NE, Ostergaard C, Kjær J, Grarup J, Lundgren JD, Procalcitonin And Survival Study (PASS) Group Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. Crit Care Med 2011, 39:2048-2058. 10.1097/CCM.0b013e31821e8791, 21572328, Procalcitonin And Survival Study (PASS) Group.